Electromed Inc. logo

Electromed Inc. (ELMD)

Market Closed
17 Jul, 20:00
AMEX AMEX
$
42. 10
-0.7
-1.6355%
$
380.8M Market Cap
32 P/E Ratio
- Div Yield
318,200 Volume
0.47 Eps
$ 42.8
Previous Close
Investors:
Add Transaction
Day Range
41.01 42.57
Year Range
17.73 47.4
Want to track ELMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ELMD closed today lower at $42.1, a decrease of -1.6355% from yesterday's close, completing a monthly increase of 13.0201% or $4.85. Over the past 12 months, ELMD stock gained 44.5245%.
ELMD is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

ELMD Chart

People also search for

Lineage Cell Therapeutics Inc.
$ 1.16
-0.8547%
Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why

Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why

Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks | 1 week ago
Here's Why Momentum in Electromed (ELMD) Should Keep going

Here's Why Momentum in Electromed (ELMD) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Electromed (ELMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks | 4 weeks ago
Electromed: Strong Margins, Strong Growth, Large Runway

Electromed: Strong Margins, Strong Growth, Large Runway

Electromed is rated 'buy' due to accelerating growth, margin expansion, and a large underpenetrated bronchiectasis market. ELMD benefits from a new CMS rule and a recently approved bronchiectasis drug, both driving increased disease awareness and streamlined clinician adoption. Gross margin improved to 78.5%, operating margin rose to 20.4%, and net income reached a record $3.0 million in Q3 FY 2026.

Seekingalpha | 1 month ago

Electromed Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Jeff Ameen
Jeff Ameen Spire Wealth Management
4,405 $73,211.3 $195,317.7 $122,106.4 166.79%
Joseph Castro
Joseph Castro Nuveen LLC
13,158 $295,260.25 $575,728.29 $280,468.04 94.99%
Jennifer Grunberg
Jennifer Grunberg Allspring Global Investments Holdings LLC
38,716 $1.13M $1.67M $542,024 48.08%
Ana-Maria Ignat
Ana-Maria Ignat Covestor Ltd
364 $8,521.24 $15,597.4 $7,076.16 83.04%
Kevin Kroskey
Kevin Kroskey True Wealth Design LLC
1 $29.5 $42.8 $13.3 45.08%

Electromed Inc. (ELMD) FAQ

What is the stock price today?

The current price is $42.10.

On which exchange is it traded?

Electromed Inc. is listed on AMEX.

What is its stock symbol?

The ticker symbol is ELMD.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 380.8M.

Has Electromed Inc. ever had a stock split?

No, there has never been a stock split.

Electromed Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
James L. Cunniff CEO
AMEX Exchange
285409108 CUSIP
US Country
180 Employees
- Last Dividend
- Last Split
13 Aug 2010 IPO Date

Overview

Electromed, Inc. is a pioneering company focusing on the advancement, manufacturing, marketing, and sales of airway clearance therapy alongside related products leveraging high frequency chest wall oscillation (HFCWO) therapy. This innovative approach is pivotal in pulmonary care for patients across various age groups both within the United States and internationally. With a foundation laid in 1992 and headquartered in New Prague, Minnesota, Electromed, Inc. is dedicated to enhancing the quality of life for individuals suffering from compromised pulmonary function due to conditions such as bronchiectasis, cystic fibrosis, and neuromuscular diseases. The company primarily serves the home health care and institutional markets, reaching its customers through physicians, health care providers, and direct patient sales.

Products and Services

  • SmartVest Airway Clearance System
  • This is a flagship product designed by Electromed, Inc., providing an effective airway clearance therapy through the application of high frequency chest wall oscillation. The system is engineered for ease of use and comfort, addressing the needs of patients with compromised pulmonary functions.

  • SmartVest SQL System
  • This system encompasses an inflatable therapy garment, a programmable air pulse generator, and a patented single hose. This hose functions to deliver air pulses from the generator to the garment, facilitating effective delivery of airway clearance therapy to the patient.

  • SmartVest Connect
  • Integrating wireless technology, SmartVest Connect offers a personalized HFCWO therapy management portal. This innovation supports improved monitoring and management of therapy, empowering patients with chronic pulmonary conditions to engage more actively in their treatment plans.

  • Single Patient Use SmartVest and SmartVest Wrap
  • Specifically designed for the acute care setting, these products cater to health care providers offering a solution for effective airway clearance on a single-patient basis. They are intended to meet the urgent needs of patients in healthcare facilities.

Contact Information

Address: 500 Sixth Avenue NW
Phone: 952 758 9299